Future Oncology

Cancer vaccines: is prevention better than cure?

• Adam E Frampton &
• Jonathan Krell

• Pages:899–901
• Published Online:15 August 2012

Tumor response criteria: are they appropriate?

• Björn LDM Brücher,
• Anton Bilchik,
• Aviram Nissan,
• Itzhak Avital &
• Alexander Stojadinovic

• Pages:903–906
• Published Online:15 August 2012

Targeting survivin’s co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy?

• Michael P Holloway &
• Rachel A Altura

• Pages:907–909
• Published Online:15 August 2012

Bulletin Board

• Pages:911–914
• Published Online:15 August 2012

Vismodegib: a promising drug in the treatment of basal cell carcinomas

• Luc Dirix &
• Annemie Rutten

• Pages:915–928
• Published Online:15 August 2012

Bevacizumab as first-line therapy for glioblastoma

• David Piccioni,
• Albert Lai,
• Phioanh Nghiemphu &
• Timothy Cloughesy

• Pages:929–938
• Published Online:15 August 2012

The double edge of the HSP90–CDC37 chaperone machinery: opposing determinants of kinase stability and activity

• Wanping Xu &
• Len Neckers

• Pages:939–942
• Published Online:15 August 2012

Glycans as targets for therapeutic antitumor antibodies

• Catherine Rabu,
• Richard McIntosh,
• Zuzana Jurasova &
• Lindy Durrant

• Pages:943–960
• Published Online:15 August 2012

Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy

• Pravin TP Kaumaya &
• Kevin Chu Foy

• Pages:961–987
• Published Online:15 August 2012

Fluid biopsy for solid tumors: a patient’s companion for lifelong characterization of their disease

• Jorge J Nieva &
• Peter Kuhn

• Pages:989–998
• Published Online:15 August 2012

Mechanisms of acquired resistance to targeted cancer therapies

• Mark R Lackner,
• Timothy R Wilson &
• Jeff Settleman

• Pages:999–1014
• Published Online:15 August 2012

EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity

• Elena Galvani,
• Godefridus J Peters &
• Elisa Giovannetti

• Pages:1015–1029
• Published Online:15 August 2012

COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature

• Karen B Chapman,
• Maria J Prendes,
• Hal Sternberg,
• Jennifer L Kidd,
• Walter D Funk,
• Joseph Wagner &
• Michael D West

• Pages:1031–1040
• Published Online:15 August 2012

10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer

• Boaz Moskovitz,
• Sarel Halachmi,
• Michal Moskovitz,
• Omri Nativ &
• Ofer Nativ

• Pages:1041–1049
• Published Online:15 August 2012

The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma

• Ilaria Imarisio,
• Chiara Paglino,
• Carlo Ganini,
• Luigi Magnani,
• Riccardo Caccialanza &
• Camillo Porta

• Pages:1051–1057
• Published Online:15 August 2012

Acknowledgements

• Page:1059
• Published Online:15 August 2012